Effect of Treatment With Metformin in Type 2 Diabetes Patients on Alternative Genes Splicing (METFORGENE)
Type 2 Diabetes

About this trial
This is an interventional basic science trial for Type 2 Diabetes
Eligibility Criteria
Inclusion Criteria:
- Type 2 Diabetic patients usually treated with metformin (≥ 1400 mg/day), associated or not to other oral anti-diabetic treatment or. injection treatment
- Patients major.
- Patients with a social security number
- Patients having signed a consent to participate in the study
Exclusion Criteria:
- Intolerance metformin
- Patients with type 1.
- Patients on pioglitazone or rosiglitazone
- Renal failure by an anomaly of the creatinine clearance (< 60 mL/min).
- Patients pregnant or likely to be.
Sites / Locations
- Centre Hospitalier Sud Francilien
Arms of the Study
Arm 1
Experimental
Arm1
During their visit of consultation on the follow-up to the type 2 diabetes, les patients will be selected on the basis of active metformin treatment at a dose greater than or equal to 1400 mg/day. Patients will have to achieve a 10 ml blood sample. The blood will be processed by Ficoll gradient centrifugation to remove the red cells and isolate circulating leukocytes: this stage will be conducted in the CERITD. Analysis on circulating leukocytes and in particular the quantification of expressions of isoforms A and B of the INSR1 by quantitative RT - PCR gene will be conducted in the laboratory of the Professor Marc Peschanski (unit INSERM 861 I - STEM of Evry). After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31.